Breast Cancer
Conditions
Interventions
Experimental group:The Kidney-Tonic and Depression-Relieving Anti-Cancer Formula (Proactive Anti-Cancer Foundation Formula: Codonopsis, Ophiopogon, Schisandra, Poria, Hedyotis, whole scorpion, raw dra
Control group:The Foundation Formula for Tonic and Anti-Cancer (Paeoniae Radix, Ophiopogon japonicus, Schisandra Chinensis, Poria cocos, Hedyotis diffusa, Scorpion, Dragon Bone and Turtle Shell, Honey
Sponsors
Beijing Shijitan Hospital Capital Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Selection criteria: (1) The patient meets the breast cancer related diagnostic criteria in the Guidelines and Norms for Breast Cancer Diagnosis and Treatment of Chinese Anti-Cancer Association (2024 edition) and has undergone surgery. The TCM syndrome is identified as liver depression and kidney deficiency syndrome (the syndrome is formulated according to the Guiding Principles for Clinical Research of New Traditional Chinese Medicine). (2) Age over 18 years old and receiving endocrine therapy within 3 months. (3) Hamilton Anxiety Scale (HAMA) score of = 7. (4) Anxiety self-rating scale (SAS) score> or = 50. (5) Survive for more than 6 months and cooperate with the investigator to complete the study. (6) Good compliance informed consent must be signed before enrollment.
Exclusion criteria
Exclusion criteria: Exclusion criteria: (1) A history of mental illness or (and) anxiety disorder. (2) Allergy to the study drug. (3) Combined cognitive or auditory and visual dysfunction. (4) Patients with severe cardiovascular and cerebrovascular diseases liver kidney hematopoietic system or other malignant tumors. (5) A history of anti-anxiety or other psychiatric drug treatment within 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TCM syndrome points;Hamilton Anxiety Rating Scale (HAMA) scores;Anxiety Self-Rating Scale (SAS) score;Breast Cancer Patient Life Quality Measurement Scale (FACT-B) score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Levels of tumor markers (CA153, CEA, CA125);estrogen level ;Records of adverse reactions;Completion of treatment;Safety indicators; | — |
Countries
China
Contacts
Public ContactPan Guofeng
Beijing Shijitan Hospital Capital Medical University
Outcome results
None listed